Results of phase 3 of the CATIE schizophrenia trial

T. Scott Stroup, Jeffrey A. Lieberman, Joseph Patrick McEvoy, Sonia M. Davis, Marvin S. Swartz, Richard S.E. Keefe, Alexander L. Miller, Robert A. Rosenheck, John K. Hsiao

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Objective: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes. Method: Two hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments. Results: Few patients selected fluphenazine decanoate (n = 9) or perphenazine (n = 4). Similar numbers selected each of the other options (range 33-41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7% overall). Conclusions: Patients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalSchizophrenia Research
Volume107
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Phase III Clinical Trials
Antipsychotic Agents
Schizophrenia
Clozapine
Perphenazine
Therapeutics
olanzapine
Risperidone
Health Status
Body Mass Index
Clinical Trials
Injections

Keywords

  • Antipsychotic
  • Clinical trial
  • Effectiveness
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Davis, S. M., Swartz, M. S., Keefe, R. S. E., ... Hsiao, J. K. (2009). Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research, 107(1), 1-12. https://doi.org/10.1016/j.schres.2008.10.011

Results of phase 3 of the CATIE schizophrenia trial. / Stroup, T. Scott; Lieberman, Jeffrey A.; McEvoy, Joseph Patrick; Davis, Sonia M.; Swartz, Marvin S.; Keefe, Richard S.E.; Miller, Alexander L.; Rosenheck, Robert A.; Hsiao, John K.

In: Schizophrenia Research, Vol. 107, No. 1, 01.01.2009, p. 1-12.

Research output: Contribution to journalArticle

Stroup, TS, Lieberman, JA, McEvoy, JP, Davis, SM, Swartz, MS, Keefe, RSE, Miller, AL, Rosenheck, RA & Hsiao, JK 2009, 'Results of phase 3 of the CATIE schizophrenia trial', Schizophrenia Research, vol. 107, no. 1, pp. 1-12. https://doi.org/10.1016/j.schres.2008.10.011
Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 2009 Jan 1;107(1):1-12. https://doi.org/10.1016/j.schres.2008.10.011
Stroup, T. Scott ; Lieberman, Jeffrey A. ; McEvoy, Joseph Patrick ; Davis, Sonia M. ; Swartz, Marvin S. ; Keefe, Richard S.E. ; Miller, Alexander L. ; Rosenheck, Robert A. ; Hsiao, John K. / Results of phase 3 of the CATIE schizophrenia trial. In: Schizophrenia Research. 2009 ; Vol. 107, No. 1. pp. 1-12.
@article{d6afb0c735c64163b94045f8b8a66879,
title = "Results of phase 3 of the CATIE schizophrenia trial",
abstract = "Objective: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes. Method: Two hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments. Results: Few patients selected fluphenazine decanoate (n = 9) or perphenazine (n = 4). Similar numbers selected each of the other options (range 33-41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7{\%} overall). Conclusions: Patients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.",
keywords = "Antipsychotic, Clinical trial, Effectiveness, Schizophrenia",
author = "Stroup, {T. Scott} and Lieberman, {Jeffrey A.} and McEvoy, {Joseph Patrick} and Davis, {Sonia M.} and Swartz, {Marvin S.} and Keefe, {Richard S.E.} and Miller, {Alexander L.} and Rosenheck, {Robert A.} and Hsiao, {John K.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.schres.2008.10.011",
language = "English (US)",
volume = "107",
pages = "1--12",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Results of phase 3 of the CATIE schizophrenia trial

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

AU - McEvoy, Joseph Patrick

AU - Davis, Sonia M.

AU - Swartz, Marvin S.

AU - Keefe, Richard S.E.

AU - Miller, Alexander L.

AU - Rosenheck, Robert A.

AU - Hsiao, John K.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Objective: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes. Method: Two hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments. Results: Few patients selected fluphenazine decanoate (n = 9) or perphenazine (n = 4). Similar numbers selected each of the other options (range 33-41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7% overall). Conclusions: Patients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.

AB - Objective: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes. Method: Two hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments. Results: Few patients selected fluphenazine decanoate (n = 9) or perphenazine (n = 4). Similar numbers selected each of the other options (range 33-41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7% overall). Conclusions: Patients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.

KW - Antipsychotic

KW - Clinical trial

KW - Effectiveness

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=58149131304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149131304&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.10.011

DO - 10.1016/j.schres.2008.10.011

M3 - Article

VL - 107

SP - 1

EP - 12

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -